Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HNGRNASDAQ:IMACNASDAQ:KYMRNASDAQ:SGRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHNGRHanger$18.72$18.70$13.42▼$22.67$732.38M1.28356,429 shsN/AIMACIMAC$0.05$0.04$0.75▼$1.65$1.32M-0.88708,132 shs1,892 shsKYMRKymera Therapeutics$44.81+0.6%$38.46$19.45▼$53.27$2.92B2.18632,626 shs240,486 shsSGRYSurgery Partners$22.15+0.6%$22.49$18.87▼$33.97$2.84B1.91.20 million shs770,143 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHNGRHanger0.00%0.00%0.00%0.00%0.00%IMACIMAC0.00%-0.20%+25.00%-15.11%-96.95%KYMRKymera Therapeutics0.00%+1.56%+1.24%+103.04%+48.57%SGRYSurgery Partners0.00%+0.91%-3.95%+4.93%-6.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHNGRHangerN/AN/AN/AN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/AN/AN/AN/AKYMRKymera Therapeutics3.1708 of 5 stars4.51.00.00.03.02.50.0SGRYSurgery Partners2.6049 of 5 stars3.41.00.00.02.00.02.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHNGRHanger 0.00N/AN/AN/AIMACIMAC 0.00N/AN/AN/AKYMRKymera Therapeutics 3.00Buy$59.1131.91% UpsideSGRYSurgery Partners 2.70Moderate Buy$33.5651.49% UpsideCurrent Analyst Ratings BreakdownLatest HNGR, IMAC, KYMR, and SGRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$70.006/27/2025KYMRKymera TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.006/26/2025KYMRKymera TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $60.006/25/2025KYMRKymera TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$64.006/3/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.006/3/2025KYMRKymera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.006/3/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$38.00 ➝ $60.006/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$49.00 ➝ $79.005/27/2025SGRYSurgery PartnersBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $24.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHNGRHanger$1.12B0.65$1.88 per share9.98$2.85 per share6.57IMACIMAC$15.22M0.09N/AN/A$0.69 per share0.07KYMRKymera Therapeutics$47.07M61.99N/AN/A$12.90 per share3.47SGRYSurgery Partners$3.11B0.91$1.87 per share11.82$25.15 per share0.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHNGRHanger$41.98M$0.9519.7115.60N/A3.17%35.72%4.00%N/AIMACIMAC-$10.54MN/A0.00N/AN/A-75.40%-52.17%-34.51%N/AKYMRKymera Therapeutics-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)SGRYSurgery Partners-$168.10M-$1.53N/A27.35N/A-6.10%2.41%0.99%8/5/2025 (Estimated)Latest HNGR, IMAC, KYMR, and SGRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025SGRYSurgery Partners$0.08$0.04-$0.04-$0.30$777.77 million$776.00 million5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHNGRHangerN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ASGRYSurgery PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHNGRHanger3.711.230.85IMACIMAC0.011.271.27KYMRKymera TherapeuticsN/A8.498.49SGRYSurgery Partners1.091.891.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHNGRHanger79.17%IMACIMAC24.27%KYMRKymera TherapeuticsN/ASGRYSurgery PartnersN/AInsider OwnershipCompanyInsider OwnershipHNGRHanger4.36%IMACIMAC10.00%KYMRKymera Therapeutics16.01%SGRYSurgery Partners2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHNGRHanger5,20039.12 million37.42 millionOptionableIMACIMAC10626.49 million23.84 millionNot OptionableKYMRKymera Therapeutics17065.12 million54.69 millionOptionableSGRYSurgery Partners15,000128.16 million125.21 millionOptionableHNGR, IMAC, KYMR, and SGRY HeadlinesRecent News About These CompaniesSurgery Partners, Inc. (NASDAQ:SGRY) Receives $33.56 Consensus PT from AnalystsJuly 5 at 2:07 AM | americanbankingnews.comCIBRA Capital Ltd Makes New Investment in Surgery Partners, Inc. (NASDAQ:SGRY)July 2 at 9:29 AM | marketbeat.comSurgery Partners, Inc. (NASDAQ:SGRY) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 2 at 2:55 AM | marketbeat.comSGRY Surgery Partners, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comSurgery Partners says no to Bain — here’s the bigger pictureJune 24, 2025 | beckersasc.comBSurgery Partners, Inc. (NASDAQ:SGRY) Shares Sold by Sivik Global Healthcare LLCJune 21, 2025 | marketbeat.comSurgery Partners (NASDAQ:SGRY) Reaches New 1-Year Low - Here's WhyJune 20, 2025 | marketbeat.comSurgery Partners Sees Unusually High Options Volume (NASDAQ:SGRY)June 20, 2025 | marketbeat.comRSI Alert: Surgery Partners (SGRY) Now OversoldJune 19, 2025 | nasdaq.comSurgery Partners: The Plunge Doesn't Justify An UpgradeJune 18, 2025 | seekingalpha.comSurgery Partners stock falls after concluding discussions with Bain CapitalJune 18, 2025 | investing.comSurgery Partners rejects Bain Capital's acquisition offer, opts to remain publicJune 18, 2025 | bizjournals.comSURGERY PARTNERS, INC. and Bain Capital Conclude DiscussionsJune 18, 2025 | finance.yahoo.comSurgery Partners declines Bain Capital bid, stays publicly listed companyJune 18, 2025 | msn.comStock Movers: JetBlue, Solar Sector, Surgery PartnersJune 18, 2025 | bloomberg.comSurgery Partners Stock Slumps 13% After Company Rejects Bain Capital’s Take-Private ProposalJune 18, 2025 | msn.comSurgery Partners rejects Bain Capital's takeover proposalJune 18, 2025 | msn.comSurgery Partners (NASDAQ:SGRY) Shares Gap Down - Here's What HappenedJune 17, 2025 | marketbeat.comSurgery Partners Rejects Bain Capital's Private Buyout Offer, Will Remain IndependentJune 17, 2025 | benzinga.comSurgery Partners rejects Bain Capital's take-private offerJune 17, 2025 | reuters.comSurgery Partners Decides to Remain IndependentJune 17, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksHNGR, IMAC, KYMR, and SGRY Company DescriptionsHanger NYSE:HNGRHanger, Inc. provides orthotic and prosthetic (O&P) services in the United States. It operates in two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and offers payor network contracting services to other O&P providers. The Products & Services segment engages in the distribution of various O&P parts, componentry, and devices to independent O&P providers; development of specialized rehabilitation technologies; and provision of evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2021, the company operated approximately 760 patient care clinics and 115 satellite locations in 47 states and the District of Columbia. It also distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.IMAC NASDAQ:IMAC$0.05 0.00 (0.00%) As of 07/3/2025IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.Kymera Therapeutics NASDAQ:KYMR$44.81 +0.28 (+0.63%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$44.81 0.00 (0.00%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Surgery Partners NASDAQ:SGRY$22.15 +0.13 (+0.59%) Closing price 07/3/2025 01:04 PM EasternExtended Trading$22.15 0.00 (0.00%) As of 07/3/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
